ATXN3 and Spinocerebellar ataxia type 3: Moreover, we have previously shown a significant reduction of mutant ATXN3 aggregation and neurological dysfunction in a C. elegans model of MJD upon VPA treatment through the protective role of the transcription factor DAF-16, supporting a role in protection against proteotoxicity related to aging and cell survival [21].